Clinical Trial Detail

NCT ID NCT03215810
Title Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

lung non-small cell carcinoma

Therapies

Nivolumab

tumor infiltrating lymphocytes

Cyclophosphamide + Fludarabine

Aldesleukin

Age Groups: adult senior

No variant requirements are available.